Impact of Extraosseous Extramedullary Disease on Outcomes of Patients with Relapsed-Refractory Multiple Myeloma receiving Standard-of-Care Chimeric Antigen Receptor T-Cell Therapy.
第一作者:
Danai,Dima
第一单位:
Department of Hematology/Oncology, Cleveland Clinic, Taussig Cancer Institute, Cleveland, OH, USA. dimad@ccf.org.;US Myeloma Innovations Research Collaborative (USMIRC), Westwood, KS, USA. dimad@ccf.org.
作者:
医学主题词
人类(Humans);多发性骨髓瘤(Multiple Myeloma);男(雄)性(Male);女(雌)性(Female);中年人(Middle Aged);老年人(Aged);免疫疗法, 过继(Immunotherapy, Adoptive);回顾性研究(Retrospective Studies);成年人(Adult);治疗结果(Treatment Outcome);护理标准(Standard of Care);肿瘤复发, 局部(Neoplasm Recurrence, Local)
DOI
10.1038/s41408-024-01068-w
PMID
38821914
发布时间
2024-11-07
- 浏览0
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文


换一批



